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Abstract In this review we summarize progress in
research on Parkinson’s disease-related pain as reported in
articles published in the Journal of Neurology in the years
2011 and 2012.
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Introduction
As well as the well-known motor symptoms, patients with
Parkinson’s disease (PD) commonly experience pain [1].
Published studies indicate a prevalence ranging from 40 to
85 % (mean 67.6 %) [2]. Pain severely impairs parkinsonian
patients’ quality of life and some patients find this non-motor
symptom more distressing than motor disturbances.
Like motor symptoms, non-motor symptoms including
pain arise through mechanisms involving nociceptive inputs
to the basal ganglia [3]. Animal experiments show that
morphine microinjected into the striatum and substantia
nigra produces a naloxone-reversible analgesia unrelated to
motor function [4]. In rats with experimentally-induced
painful neuropathy striatal activity increased and opioids
suppressed this increase [5]. Nociceptive inputs travel to the
striatum from the various pain-related cortical areas
including SII, insula, cingulate cortex, prefrontal areas, and
thalamic intralaminar nuclei [6]. The nociceptive-responsive
striatal neurons have large receptive fields and strongly
respond as the noxious input increases in intensity, thus
suggesting that rather than spatially localizing pain the stri-
atum codes its nociceptive input intensity [7]. The basal
ganglia also connect with several pain-related areas. Sub-
stantia nigra efferent pathways connect to amygdala, pre-
frontal cortex and cingulate cortex, areas involved in the
motivational-affective pain dimension [8]. Neuroimaging
studies in humans show that pain modulation involves stri-
atal dopamine D2 receptors [9]. All these data suggest that
abnormal basal ganglia function in PD modulates pain
directly by increasing or diminishing nociceptive signal
propagation, and indirectly by influencing affective and
cognitive processes thereby regulating how patients expect,
experience and interpret nociceptive signals and pain.
Patients with PD experience two different types of pain,
nociceptive and neuropathic. Nociceptive pains are extre-
mely frequent (accounting for 40–90 % of reported pain)
[1]. Nociceptive pain related to PD is typically musculo-
skeletal and visceral. Musculoskeletal pain usually origi-
nates from abnormal posture, rigidity, and akinesia causing
motor fluctuations, thus leading to painful dystonia. The
most typical painful dystonia, reported by about 40 % of
patients with PD, is that manifesting in the early morning,
when dopaminergic stimulation is low and akinesia and
rigidity are severe. Early morning dystonia manifests as a
focal dystonia with plantar flexion and foot inversion.
Another frequent type of nociceptive pain is the visceral
pain that frequently accompanies constipation. Bowel
functioning in patients with PD depends on several factors
including autonomic failure involving the enteric nervous
system. Dystonic contractions involving the anal sphincter
can cause painful anismus.
PD-related neuropathic pain comprises radicular pain
and central Parkinson’s pain. Radicular pain has a higher
prevalence in patients with PD than in the general popu-
lation (14–35 % vs. 10 %) [1, 10]. This high frequency
A. Truini  M. Frontoni  G. Cruccu (&)
Department of Neurology and Psychiatry, University Sapienza,
Viale Universita` 30, 00185 Rome, Italy
e-mail: cruccu@uniroma1.it
123
J Neurol (2013) 260:330–334
DOI 10.1007/s00415-012-6754-5
probably reflects the lumbar discal structure damage due to
festination, kyphosis and dystonia. Pain directly related to
PD (central Parkinson’s pain) is a relatively rare condition
(4–10 % of patients) [1, 11]. It mainly affects the body side
with predominant motor symptoms and patients usually
describe it as a burning, cramping sensation. Unlike
‘‘classic’’ central pain, central Parkinson’s pain has no
association with the clinically evident sensory deficits that
reflect afferent pathway damage [12]. Although the data
argues against the currently accepted criteria for defining
neuropathic pain given that the diagnosis requires a sensory
deficit, most investigators believe that this type of pain
arises directly from basal ganglia dysfunction that alters
sensory processing of nociceptive inputs [1, 11].
Over the past 2 years interest in problems related to pain
in PD has enormously increased. This article reviews and
summarizes the new findings in PD-related pain published
in the Journal of Neurology in the years 2011 and 2012.
Clinical information on pain related to PD
Virtually all patients with PD have non-motor symptoms,
the most frequent being psychiatric symptoms and pain
[13]. Non-motor symptoms may even, though rarely, pre-
cede the onset of the typical motor disorders. This pre-
motor stage reflects the early structural changes taking
place in the lower brainstem nuclei and peripheral nervous
system, including the autonomic and enteric ganglia.
Identifying the pre-motor stage could be clinically useful,
because early treatment might influence the disease course,
improving the long-term outcome. Pain is one of the most
common pre-motor symptoms of PD, and can affect the
patient’s life for years before PD is diagnosed. In their
study highlighting the importance and high frequency of
pain as a non-motor symptoms, Winkler and colleagues
[14] proposed a PD risk score, grading various non-motor
items including pain to define a risk profile for identifying
patients with PD who might benefit from disease-modify-
ing strategies. Whether managing PD early implies a better
outcome also in non-motor symptoms, such as pain, is an
open matter. To answer the question we need studies
designed to assess the PD-related pain burden in relation-
ship to disease-modifying drugs and treatment timing.
Although most studies report that PD-related pain is
significantly more frequent in women than in men [11],
some articles state the contrary [15]. Aiming at analysing
the gender differences in non-motor PD symptoms,
including pain, Martinez-Martin and colleagues studied for
study 950 patients with PD [16]. Using the Non-Motor
Symptom Score they investigated 30 items, including pain.
Whereas no differences were found in age, age at onset,
duration of disease, and motor disability between genders,
pain was significantly more frequent in women than in
men. This gender-related difference in pain in PD is in line
with the many epidemiological studies showing that vari-
ous acute and chronic pains, such as headache, oro-facial,
musculoskeketal and abdominal pains are more frequent in
women than in men. Although some sex-related differences
in pain might reflect cognitive and social factors, the lower
pain threshold and pain tolerance in women might arise
partly from biological differences. Several experimental
studies have documented gender differences in opioid
analgesia suggesting that the endogenous pain inhibitory
system is less efficient in women than in men [17]. The
gender differences in PD-related pain, reported in the study
by Martin and colleagues, could be used to improve pain
management in PD for both genders, and analyze gender-
related differences in outcome after similar treatments.
Although many studies show that PD-related pain
adversely influences patients’ quality of life [18, 19], no
study has investigated how pain affects daily activities. The
study by Trail and colleagues [20], examining the rela-
tionships among activity and daily energy expenditure,
non-motor symptoms and body mass index, surprisingly
demonstrates that pain affects patients’ daily activities
more than their memory problems and depression.
Although this study admirably highlights the pain burden
in daily activity in PD, unfortunately, because it was con-
ducted in a veteran’s hospital, it almost exclusively
enrolled men (98 %). Because pain is more frequent and
severe in women than in men [21], this collection bias
might weaken the study’s clinical significance on the
impact of pain in patients with PD.
Managing PD and its related non-motor symptoms,
including pain, exacts a considerable economic burden,
especially given worldwide population aging. Intense
research efforts, therefore, focus on reducing costs by
developing new treatments and models for care. These
developments oblige the national reimbursement agencies
to undertake an accurate cost-effectiveness analysis.
Although many studies have examined how non-motor
symptoms and pain influence quality of life, little is known
about health state utility values (the measure used in health
economics for assessing the individual’s preferences for
different health outcomes). In their study [22] in patients
with a recently diagnosed PD, Shearer and colleagues have
investigated health state utility values and estimated their
clinical and demographic correlates for future economic
studies. Besides providing data useful for cost-effective-
ness analysis the investigators also report that pain can
have a greater impact on quality of life than motor symp-
toms, thus underlining how important it is to manage non-
motor symptoms more effectively in newly diagnosed PD.
Although the many studies addressing the problem of
non-motor symptoms in PD have reported their high
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frequency and clinical importance, they used only short-
term prospective observation periods. Hence, we know
little about how these symptoms progress and how they
contribute to deteriorating quality of life during the disease
course. As the disease progresses, rigidity and akinesia
producing musculoskeletal abnormalities and fluctuating
motor symptoms causing painful dystonia (such as the
early morning dystonia) increase [23]. Hence, the fre-
quency and severity of pain should increase in parallel. The
large prospective PRIAMO study (Parkinson’s and non-
motor symptoms) [24] collecting 707 patients and assess-
ing symptoms related to 12 different non-motor domains
over 24 months reports that as overall non-motor symp-
toms increase in number along with disease motor severity
and duration. But whereas some domains such as sleep,
gastrointestinal symptoms, attention/memory disturbances
and skin disorders (hyperhidrosis and seborrhoea) become
more prevalent, psychiatric, cardiovascular, and respiratory
symptoms become less prevalent. Unexpectedly, the fre-
quency and clinical importance of pain remained basically
stable. The study reported that the number of patients
complaining of pain increased by only 1 %, and the
39-item Parkinson’s Disease Questionnaire (PDQ-39), the
scale used for quality of life assessment [25] remained
unchanged. Although this study provides the previously
unavailable information on how pain influences disease
progression and quality of life in PD it has two important
limitations. It fails to assess symptom severity, or take
medications into account. One reason why the study by
Antonini et al. [23] found no significant differences in pain
incidence might be that patients changed the pain-killers or
antiparkinsonian medications they used during the study.
Consistently, in most patients (more than 80 %) the Hoehn
and Yahr scale remained unchanged during follow-up, thus
suggesting stable motor control, probably because phar-
macological treatment changed during the course of the
disease. Further studies investigating pain progression
should probably include data for medications used in their
results.
Pathophysiology
Whereas animal studies underline the role of the basal gan-
glia and dopaminergic transmission in pain, the mechanisms
underlying pain related to PD in humans remain unclear.
Currently only indirect evidence suggested nociceptive
system dysfunction in patients with PD. The study by
Zambito and colleagues [26] adds information on how PD
can put patients at higher risk of pain than healthy subjects.
Using electrical stimulation they assessed tactile threshold,
pain threshold, and pain tolerance in 106 PD patients (66 of
whom had chronic pain). They found that pain threshold and
pain tolerance were significantly lower in PD patients than in
control subjects, whereas tactile threshold values were
comparable in both groups. Surprisingly pain threshold and
pain tolerance tend to lower as PD progresses, thus sug-
gesting that as basal ganglia dysfunction worsens, nocicep-
tive system involvement increases. Unexpectedly no
difference was found in pain thresholds and pain tolerance
between PD patients with and without pain. This finding
seems to argue against the possibility that decreased sensory
thresholds play some role in the development of pain in PD
patients, but when Zambito et al., analyzed sensory thresh-
olds they failed to distinguish between neuropathic and
nociceptive pain. This distinction is important because
whereas nociceptive pain is presumably unrelated to changes
in sensory thresholds, neuropathic pain, a pain type that
directly involves the nociceptive pathways, is associated
with abnormal sensory thresholds [27].
Treatment options
The treatment of PD-related pain hinges on empirical data
alone and no large randomized controlled data are avail-
able. The pharmacological management relies on antipar-
kinson, antinociceptive and antineuropathic medications.
Deep brain stimulation (DBS) targeted to the subthalamic
nucleus and globus pallidus, a surgical procedure widely
used for treating motor disorders in PD [28, 29], effectively
relieves various types of PD-related pain, such as muscu-
loskeletal, dystonic and central Parkinson pain [30, 31].
Despite these successful DBS applications in their pro-
spective study, Capelle and colleagues [32] showed that
DBS targeted to the subthalamic nucleus and globus pal-
lidus has only a mild and negligible effect on an unusual
type of PD-related pain: the back pain due to camptocormia
(the rare and disabling condition provoking abnormal trunk
flexion). This finding implies that this condition, unlike
segmental dystonia, arises through other still unknown
mechanisms, insensitive to DBS. The study conducted by
Capelle et al. provides useful information indirectly sup-
porting the idea that PD-related pain is a heterogeneous
condition arising through multiple and diverse mecha-
nisms, and may help in defining a PD pain profile that
responds to DBS [33].
Conclusions and future directions
Studies dealing with PD-related pain published in the
Journal of Neurology over the past 2 years highlighting the
importance of pain in PD have provided new insights into
this common problem. Despite advancing our knowledge
in this field they leave many questions open. Most
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important, how should we categorize PD-related pain? Few
studies reliably distinguish the various types of PD-related
pain. Because the various types of pain arise from different
mechanisms, and probably respond differently to treatment
[34], the major need is to classify pain according to its
pathophysiological mechanisms and use the information to
plan reliable pharmacological trials.
Although no randomized controlled trials have yet
investigated PD-related pain, some pharmacological and
non-pharmacological trials are now underway (www.
clinicaltrial.gov). We hope they will provide the informa-
tion on treatment that can translate into clinically important
advances for patients with PD.
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